Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 2, and Neuropilin-1 (VEGFR1/VEGFR2/NRP1)

The Vascular Endothelial Growth Factor (VEGF) pathway, comprising VEGFR1, VEGFR2, and Neuropilin-1 (NRP1), is the primary driver of angiogenesis and vascular development (UniProt P35968). VEGFR2 is the major signal transducer for endothelial cell proliferation and migration, while VEGFR1 often acts as a decoy receptor to regulate VEGF-A bioavailability (NCBI Bookshelf NBK542187). Neuropilin-1 serves as a crucial co-receptor that stabilizes the VEGF-A/VEGFR2 complex, significantly enhancing signaling efficiency (UniProt O14786). In many cancers, tumors overexpress VEGF to stimulate the growth of new blood vessels, a process essential for tumor expansion and metastasis (PubMed PMC3567541). This pathway is also implicated in ocular diseases like wet age-related macular degeneration, where excessive vessel growth leads to vision loss (StatPearls NBK448169). Pharmacological intervention includes monoclonal antibodies like bevacizumab that neutralize VEGF, and receptor-targeted antibodies like ramucirumab (FDA Label). Additionally, small-molecule tyrosine kinase inhibitors such as sunitinib and axitinib block the intracellular signaling of VEGFR1 and VEGFR2 (PubChem CID 5329102). Clinical use of these inhibitors requires monitoring for side effects like hypertension and proteinuria, which are direct consequences of systemic VEGF inhibition (PubMed PMC4412761). Overall, this receptor complex represents one of the most successful therapeutic targets in modern oncology and ophthalmology.

Other names

Flt-1KDRFlk-1CD304BDCA4Vascular permeability factor receptorVEGF Receptor 1VEGF Receptor 2Neuropilin 1

Inhibition of the VEGF signaling axis through ligand sequestration, competitive blockade of extracellular receptor binding sites, or ATP-competitive inhibition of intracellular tyrosine kinase domains.